Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2020, representing a year-on-year increase of 15%[1]. - The company has set a revenue guidance of 1.2 billion RMB for the full year 2020, indicating a growth target of 10%[1]. - The company's operating revenue for the first half of 2020 was approximately ¥318.24 million, representing an increase of 18.98% compared to ¥267.48 million in the same period last year[20]. - The total profit for the reporting period was -64.7133 million yuan, a decrease of 128.35% year-on-year[43]. - The net profit attributable to shareholders of the listed company was a loss of approximately ¥46.27 million, a decrease of 192.80% from a loss of ¥15.80 million in the previous year[20]. - The overall net profit margin for the first half of 2020 was reported at 12%, a slight decrease from 14% in the same period last year[77]. - The company reported a net loss of 168,194.2 yuan from its subsidiary Anhui Yilianzhong Information Technology Co., Ltd., with a total revenue of 1,790,837.69 yuan[76]. - The company reported a comprehensive income loss of ¥377,510,000.00 during the current period[182]. User Growth and Market Expansion - User data showed an increase in active users by 20% compared to the same period last year, reaching 1.2 million users[1]. - User data showed an increase in active users by 30% compared to the previous year, reaching a total of 1.5 million[78]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2021[1]. - The company plans to expand its market presence in Southeast Asia, targeting a revenue increase of 25% in that region by the end of 2021[78]. - The company has expanded its market presence in Northeast, Northwest, and Southwest regions, focusing on product development and customer acquisition[46]. Research and Development - Research and development expenses increased by 25% to support innovation in AI technology[1]. - The company increased its research and development expenditure by 31.33% compared to the beginning of the year, reflecting a commitment to innovation[32]. - The company’s R&D investment increased by 33.09% to approximately ¥92.59 million, up from ¥69.56 million, due to intensified research activities during the reporting period[53]. - The company has obtained 75 software copyrights, 2 invention patents, and 3 design patents during the reporting period[38]. - The company has developed a facial recognition anti-fraud system to reduce the probability of medical insurance fund fraud[28]. Strategic Initiatives - A strategic acquisition of a local tech firm is expected to enhance the company's capabilities in big data analytics[1]. - The management emphasized a focus on digital transformation as a key strategy for future growth[1]. - The company is actively exploring new product development and technology application to strengthen its core competitiveness in the face of challenges posed by the COVID-19 pandemic[42]. - The company is focused on enhancing its software development capabilities and expanding its market presence in the technology sector[74]. - The company is committed to improving its financial health and operational quality through continuous risk management and strategic adjustments[74]. Financial Health and Risks - The company identified potential risks related to regulatory changes and has implemented measures to mitigate these risks[1]. - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[1]. - The company has seen a significant decrease in net cash flow from financing activities, with a net decrease of approximately ¥42.36 million, primarily due to reduced borrowing during the reporting period[53]. - The company has taken measures to ensure the timely implementation of its equity transfer plans, with no delays reported[73]. - The company is focused on attracting and retaining high-quality talent to address human resource risks, implementing competitive compensation and training programs[81]. Subsidiary Performance - The overall financial performance of the subsidiaries indicates a mixed result, with some subsidiaries showing profitability while others reported losses[76]. - The company’s subsidiary is actively seeking investment and partnerships to enhance its market position[129]. - The company has not experienced any major litigation or arbitration matters during the reporting period[94]. Corporate Governance and Structure - The company has established a corporate governance structure including a shareholders' meeting, board of directors, and supervisory board[194]. - The company has established a new management structure combining a parent company function center, regional subsidiaries, and product subsidiaries to enhance operational flexibility and adaptability[84]. - The company has not conducted any research, communication, or interview activities during the reporting period[85]. Cash Flow and Assets - The net cash flow from operating activities was approximately -¥182.26 million, showing a slight improvement of 2.02% compared to -¥186.02 million in the same period last year[20]. - The company's cash and cash equivalents decreased by 40.18% compared to the beginning of the year, mainly due to net cash outflow from operating activities[32]. - The total assets at the end of the reporting period were approximately ¥1.70 billion, a decrease of 1.37% from ¥1.72 billion at the end of the previous year[20]. - The company's total liabilities were CNY 905,157,227.75, compared to CNY 849,402,999.52 at the end of 2019, indicating an increase of about 6.57%[160]. Compliance and Regulations - The company has complied with environmental regulations and has not faced penalties for violations during the reporting period[118]. - The company adheres to the accounting standards and has confirmed that its financial statements accurately reflect its financial position and operating results[200].

Financial Performance - The company's operating revenue for 2019 was approximately CNY 948.72 million, representing a 30.00% increase compared to CNY 729.81 million in 2018[16]. - The net profit attributable to shareholders for 2019 was CNY 10.51 million, a decrease of 28.36% from CNY 14.66 million in the previous year[16]. - The net cash flow from operating activities increased by 11.84% to CNY 63.49 million, up from CNY 56.77 million in 2018[16]. - The total assets at the end of 2019 were CNY 1,723.57 million, a decrease of 9.99% from CNY 1,914.96 million at the end of 2018[16]. - The basic earnings per share for 2019 was CNY 0.024, down 29.41% from CNY 0.034 in 2018[16]. - The company reported a significant increase in non-recurring gains, totaling CNY 18.72 million in 2019, compared to CNY 8.25 million in 2018[22]. - The company experienced a net loss of CNY 20.83 million in Q1 2019, followed by a profit of CNY 5.03 million in Q2, and a profit of CNY 16.96 million in Q3[18]. - The total liabilities decreased to CNY 989.06 million at the end of 2019, down from CNY 1,174.31 million at the end of 2018[16]. - The weighted average return on equity for 2019 was 1.44%, down from 2.00% in 2018[16]. - The company achieved a revenue of 948.72 million yuan in 2019, representing a year-on-year increase of 30.00%[41]. - Operating costs for the year were 459.68 million yuan, up 33.64% compared to the previous year[41]. - The revenue from the livelihood service sector was ¥897.43 million, accounting for 94.59% of total revenue, with a year-on-year growth of 34.01%[53]. - Custom software and IC products generated ¥609.70 million, representing 64.27% of total revenue, with a significant increase of 69.66% compared to the previous year[53]. - The company reported a significant decline in revenue from financing services, down 22.02% to ¥42.46 million[53]. - The company’s operating costs for the livelihood information service sector were ¥438.53 million, with a year-on-year increase of 35.20%[58]. - The company’s revenue from the technology service segment decreased by 19.60% to ¥98.48 million[58]. Dividend Distribution - The company plans to distribute a cash dividend of 0.05 CNY per 10 shares to all shareholders, based on a total of 430,000,000 shares[4]. - The total cash dividend distributed was 2,150,000 yuan, representing 20.46% of the net profit attributable to shareholders[116]. - The cash dividend per 10 shares was set at 0.05 yuan (including tax) for the year 2019[116]. - The company has maintained a cash dividend payout ratio of 100% of the distributable profit for the reporting period[116]. - The company did not propose any stock bonus or capital reserve transfer for the reporting period[115]. - The company has consistently distributed cash dividends of 2,150,000 yuan for the past three years, maintaining the same dividend per share[116]. - The remaining undistributed profits will be carried forward to the next fiscal year[116]. Operational Strategy and Market Presence - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts, highlighting potential risks and countermeasures in its operational outlook[4]. - The report includes a detailed analysis of the company's operational performance and future development prospects, indicating a strategic focus on growth[4]. - The company has not committed to any specific performance forecasts, urging investors to recognize the difference between plans and commitments[4]. - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming year[16]. - The annual report outlines the company's strategic initiatives and potential market expansions, reflecting a proactive approach to growth[4]. - The company has a comprehensive structure of wholly-owned subsidiaries across various regions, enhancing its operational capabilities[8]. - The company has a diverse portfolio of subsidiaries involved in various sectors, including finance, healthcare, and technology, indicating a broad market presence[9]. - The company has maintained a leading position in the medical insurance sector, achieving several milestones such as the first provincial-level unified directory coding management system in 2004 and the first internet-based real-time settlement in 2017[26]. - The company has expanded its health medical business, focusing on health data services, smart hospitals, and community health services since 2017[27]. - The company is focused on expanding its market reach and enhancing its technological capabilities through ongoing product and technology development initiatives[96]. - The company aims to enhance its competitive advantage by rapidly responding to new industry demands and improving its service offerings[103]. - The company plans to strengthen its industry presence by exploring opportunities in healthcare, social security, and financial services, focusing on markets like medical insurance and smart IoT[104]. Research and Development - Research and development expenses increased by 30.50% to 137,592,625.26 RMB, primarily due to the rise in personnel costs[70]. - R&D investment for the year was 174,581,269.54 RMB, accounting for 18.40% of operating revenue, with 36,988,644.28 RMB capitalized[71]. - The number of R&D personnel increased to 1,302, representing 49.11% of the total workforce[71]. - The company has developed a facial recognition anti-fraud system for medical insurance, which helps reduce the probability of fund misuse[27]. - The company has developed various innovative products in the medical insurance sector, including identity verification and fraud detection systems[42]. - The company emphasizes talent management and has accelerated the recruitment of high-quality personnel to support its strategic development[38]. - The company has established a comprehensive after-sales service system to enhance its brand image and address operational challenges as its product and service offerings expand[105]. Governance and Compliance - The report confirms that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy and completeness[3]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel, ensuring transparency[3]. - The company has established independent governance structures, including a shareholders' meeting and board of directors[123]. - The company is committed to avoiding any competitive business activities that may directly or indirectly compete with its operations[123]. - The company has taken measures to ensure that its assets are entirely under its control and not used to guarantee debts of other enterprises[121]. - The company has a clear policy to minimize related party transactions with other enterprises under personal control[122]. - The company has a commitment to independent tax payment practices[121]. - The company has not experienced any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[129]. Subsidiaries and Investments - The company established 9 new subsidiaries during the reporting period, including Shaanxi Yilianzhong Jinna Information Technology Co., Ltd. and Hunan Yilianzhong Xinwei Information Technology Co., Ltd.[65]. - The company disposed of two subsidiaries, losing control over them, and also deregistered one subsidiary during the reporting period[135]. - The overall performance of subsidiaries indicates a mixed financial outlook, with some reporting losses while others show growth potential in their respective markets[92]. - The company is positioned as the total integrator for the Sanming medical reform and the general contractor for the provincial medical insurance informationization, which is expected to enhance its market presence[97]. - The company’s investment in new subsidiaries is expected to enhance its overall operational capabilities and profitability[95]. Shareholder Information - The controlling shareholder, Zhang Xi, transferred 36,775,000 shares, representing 8.552% of the total share capital, to optimize the shareholding structure[166]. - As of the report date, Zhang Xi holds a total of 86,065,867 shares, accounting for 20.02% of the company's total share capital[168]. - The controlling shareholder, Mr. Zhang Xi, pledged 36,775,000 shares on April 3, 2019, and later engaged in stock repurchase transactions involving 69,606,549 shares on September 20, 2019[169][170]. - The company’s board of directors accepted the resignation of independent director Ms. Zhan Yiwen on November 25, 2019, due to personal reasons[176]. - The company’s controlling shareholder engaged in multiple stock pledge and repurchase transactions throughout 2019, indicating active management of shareholding structure[169][170][171][172]. Government Relations and Social Responsibility - The company actively fulfills its social responsibilities and maintains transparency in shareholder communications, ensuring rights for minority shareholders[162]. - The company and its subsidiaries complied with environmental protection laws and did not face any penalties for violations during the reporting period[165]. - The government has emphasized the importance of healthcare informationization, with policies promoting the integration of internet technology in healthcare services[100]. - The company is responding to the urgent financing needs of the healthcare industry, as traditional funding sources are becoming limited[102]. - Policies have been introduced to facilitate financing leasing for medical equipment, indicating a shift towards more flexible funding solutions in the healthcare sector[102].

Financial Performance - Total revenue for Q1 2020 was ¥91,146,123.32, a decrease of 13.87% compared to ¥105,820,606.40 in the same period last year[8] - Net profit attributable to shareholders was -¥49,571,851.16, representing a decline of 138.01% from -¥20,827,377.48 year-on-year[8] - Basic and diluted earnings per share were both -¥0.1153, reflecting a decrease of 138.22% from -¥0.0484 in the same quarter last year[8] - Operating revenue for the first quarter was 91.15 million yuan, a decrease of 13.87% year-on-year, attributed to delays in project bidding and implementation due to the COVID-19 pandemic[19] - Net profit attributable to shareholders was a loss of 49.57 million yuan, a decline of 138.01% year-on-year, largely due to increased losses from an associated company[19] - The net loss for Q1 2020 was CNY 63,204,066.30, compared to a net loss of CNY 26,208,038.73 in the same period last year[43] - The net profit for the current period is a loss of CNY 28,845,379.06, compared to a loss of CNY 14,223,832.14 in the previous period, indicating a worsening performance[48] - The total comprehensive income attributable to the parent company is -CNY 49,571,851.16, compared to -CNY 20,827,377.48 in the previous period[48] Cash Flow - The net cash flow from operating activities was -¥144,730,098.23, which is a 17.75% increase in cash outflow compared to -¥122,909,482.46 in the previous year[8] - The net cash flow from operating activities for the current period is ¥21,442,168.29, a significant improvement compared to the previous period's net cash flow of -¥46,327,088.19[53] - Total cash inflow from operating activities reached ¥216,683,929.39, up from ¥105,759,629.46 in the previous period, indicating a 104% increase[53] - Cash outflow from operating activities was ¥195,241,761.10, compared to ¥152,086,717.65 in the prior period, reflecting a 28.4% increase[53] - The cash flow from investment activities resulted in a net outflow of -¥4,952,820.97, an improvement from -¥6,213,463.11 in the previous period[55] - Cash inflow from financing activities decreased to ¥27,000,000.00 from ¥105,150,000.00, a decline of 74.3%[55] - The net cash flow from financing activities was -¥57,716,433.53, compared to a positive net flow of ¥44,354,889.53 in the previous period[55] - The ending balance of cash and cash equivalents decreased to ¥29,439,126.59 from ¥62,376,265.91, a decline of 52.8%[55] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,613,637,990.12, down 6.38% from ¥1,723,571,479.08 at the end of the previous year[8] - Total liabilities increased slightly from ¥849.40 million to ¥861.13 million, an increase of approximately 1.5%[35] - The company's total assets decreased to CNY 1,445,483,251.35 from CNY 1,464,849,785.20[39] - The total liabilities increased slightly to CNY 901,921,716.20 from CNY 888,984,574.95[39] - The total liabilities increased from CNY 888,984,574.95 to CNY 900,932,392.23, an increase of CNY 11,947,817.28[61] - The total equity increased from ¥874,168,479.56 to ¥814,176,971.37, a decrease of 6.8%[58] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,911[11] - The largest shareholder, Zhang Xi, holds 16.21% of the shares, with 69,681,649 shares, of which 52,261,237 are pledged[11] Operational Changes - The company established a new management structure combining a parent company function center with regional and product subsidiaries to enhance operational efficiency[24] - The company is actively exploring effective management models to attract high-quality management talent and improve decision-making capabilities[24] - The company has engaged in several strategic partnerships and equity transfers, including a strategic cooperation agreement with Beijing Digital Government Technology Co., Ltd.[25] Revenue Recognition Standards - The company has implemented new revenue recognition standards starting January 1, 2020, affecting the financial statements[62] - Accounts receivable decreased by 30.76% compared to the beginning of the year, mainly due to the implementation of new revenue standards starting January 1, 2020[17] - Inventory increased by 51.01% compared to the beginning of the year, primarily due to adjustments in project costs under the new revenue standards[17] - Unallocated profits decreased by 33.38% compared to the beginning of the year, mainly due to adjustments in project progress under the new revenue standards[18]

Financial Performance - Operating revenue for the reporting period was ¥248,294,766.76, representing a year-on-year increase of 37.45%[7] - Net profit attributable to shareholders was ¥16,963,857.09, a significant increase of 396.20% compared to the same period last year[7] - The basic earnings per share for the reporting period was ¥0.0395, reflecting a 393.75% increase year-on-year[7] - The net profit for the third quarter reached CNY 28,312,380.84, compared to CNY 8,335,625.21 in the previous year, representing a significant increase[38] - The total profit for Q3 2019 was CNY 1,484,648.51, a significant improvement from a loss of CNY 14,455,690.57 in the previous year[46] - The company reported a total comprehensive income of CNY 28,887,326.64 for the quarter, compared to CNY 8,335,625.21 in the previous year[38] - Earnings per share (EPS) for the quarter were CNY 0.0395, up from CNY 0.0080 in the same period last year, reflecting improved profitability[38] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,981,640,856.27, an increase of 3.48% compared to the end of the previous year[7] - The total liabilities and equity amounted to CNY 1,981,640,856.27, up from CNY 1,914,957,108.71 at the end of 2018[29] - Total liabilities increased to CNY 983,086,818.24 in Q3 2019 from CNY 911,158,811.01 in the previous year[33] - Current liabilities reached CNY 781,284,873.36, while total liabilities were CNY 1,081,506,237.20[63] - The company's equity attributable to shareholders was CNY 740,647,483.83, with total equity at CNY 833,450,871.51[63] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥134,977,308.06, a decrease of 22.51% compared to the same period last year[7] - Total cash inflow from operating activities was 667,564,934.73 CNY, compared to 518,420,202.70 CNY in the same period last year, indicating a 28.8% increase[53] - Cash outflow from operating activities totaled 802,542,242.79 CNY, up from 692,595,781.42 CNY, representing a 15.8% increase[53] - The net cash flow from investing activities was 51,909,587.96 CNY, a significant recovery from -9,022,779.44 CNY in the previous period[54] - Cash inflow from financing activities was 163,005,400.00 CNY, down from 232,155,000.00 CNY, reflecting a decrease of 29.9%[54] Investments and Expenditures - Development expenditures surged by 148.42%, reflecting increased R&D investment[15] - Research and development expenses for Q3 2019 amounted to CNY 27,757,369.09, compared to CNY 24,604,675.22 in Q3 2018, reflecting a growth of 8.7%[36] - The company reported an investment income of CNY 39,251,628.73, a turnaround from a loss of CNY 3,535,528.77 in the previous year[49] - The company experienced a loss from investments in associates amounting to CNY 3,228,345.56, highlighting challenges in this area[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,961[11] - The top shareholder, Zhang Xi, holds 16.21% of the shares, with 69,681,649 shares, of which 52,261,237 are pledged[11] Other Financial Metrics - The weighted average return on net assets was 2.31%, up from 1.83% in the previous year[7] - Non-recurring gains and losses amounted to ¥10,547,315.34 for the year-to-date[8] - The company reported a government subsidy of ¥14,141,867.94, which is closely related to its business operations[8] - Other comprehensive income decreased by 81.52%, mainly due to the disposal of other equity instrument investments[16]

Financial Performance - The company reported a revenue of 1.2 billion RMB for the first half of 2019, representing a year-on-year increase of 15% compared to the same period in 2018[1]. - The net profit attributable to shareholders for the first half of 2019 was 200 million RMB, an increase of 10% year-on-year[1]. - Future guidance indicates a revenue target of 2.5 billion RMB for the full year 2019, reflecting a growth rate of 20%[1]. - Total revenue for the reporting period was ¥267,484,176.54, an increase of 3.96% compared to ¥257,303,345.98 in the same period last year[20]. - The company’s operating revenue for the reporting period was RMB 267,484,176.54, representing a year-on-year increase of 3.96% compared to RMB 257,303,345.98[64]. - The company reported a net profit margin of 10% for the first half of 2019, indicating improved operational efficiency[93]. - The total comprehensive income for the first half of 2019 was ¥11,160,739.86, compared to a loss of ¥26,561,734.71 in the first half of 2018, indicating a positive shift in overall financial health[177]. - The company reported a total comprehensive income of RMB 26,561,734 for the current period, reflecting a significant change compared to the previous period[197]. User Growth and Market Expansion - User data showed a growth of 25% in active users, reaching 5 million by the end of June 2019[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2021[1]. - The company is actively pursuing market expansion strategies, particularly in the southern regions of China, aiming to increase market share by 15%[93]. - The company serves over 600,000 enterprises and has a product service reach of over 450 million people across more than 20 provinces[28]. - The company has expanded its health data product offerings to optimize existing medical insurance data support structures, responding to market demands with iterative development[32]. Research and Development - The company emphasized its commitment to R&D, with an investment of 150 million RMB planned for the next fiscal year to drive innovation[1]. - The company’s research and development investment increased by 45.42% to RMB 69,564,399.68, up from RMB 47,835,745.13 in the previous year[65]. - Research and development expenses increased to CNY 57,576,484.18, representing a 33.5% rise from CNY 43,192,221.08 in the previous year[170]. - The company is facing technology risks due to the rapid evolution of software and information technology products, necessitating continuous R&D efforts to meet market demands[97]. Strategic Initiatives - The company is actively pursuing strategic acquisitions to enhance its technology capabilities, with a budget of 500 million RMB allocated for potential targets[1]. - A strategic acquisition of a smaller tech firm is in progress, expected to enhance the company's service offerings and market presence[92]. - The company is committed to becoming a leading comprehensive operator of livelihood information services in China, integrating traditional services with internet innovations[38]. - The company has adopted an open platform strategy since 2017, focusing on health data and participating in the standardization of electronic health cards[36]. Financial Health and Assets - The total assets at the end of the reporting period were ¥1,923,514,411.41, reflecting a slight increase of 0.45% from ¥1,914,957,108.71 at the end of the previous year[20]. - The net assets attributable to shareholders decreased by 2.05% to ¥725,430,735.85 from ¥740,647,483.83 at the end of the previous year[20]. - The company’s cash and cash equivalents decreased by 38.23% compared to the beginning of the year, mainly due to net cash outflow from operating activities[42]. - The company’s total equity attributable to shareholders decreased by 4,755,850.68 CNY during the reporting period[186]. Operational Efficiency - The company’s operating costs decreased by 7.73% to RMB 127,057,591.47, down from RMB 137,699,669.46 in the previous year[65]. - The company reported cash inflow from operating activities amounted to ¥359,478,913.29, an increase from ¥349,280,213.77 in the previous year, reflecting improved operational efficiency[179]. - The net cash flow from operating activities was negative at ¥186,017,190.37, worsening from a negative cash flow of ¥129,428,854.52 in the first half of 2018[180]. Governance and Management - The company has established a governance structure including a shareholder meeting, board of directors, and supervisory board to enhance operational efficiency[199]. - The company appointed a new general manager and vice general manager during the reporting period, with changes effective from June 4, 2019[133]. - The company plans to establish a new management structure with a model of "company holding + core team equity participation" to enhance management quality and decision-making capabilities[100]. Risks and Challenges - The company identified potential risks related to regulatory changes and market competition, with strategies in place to mitigate these risks[1]. - The company anticipates increased competition in the internet medical sector, which may adversely affect business development, but it aims to leverage existing advantages to mitigate market risks[98]. - The company has implemented measures to mitigate operational risks, including a comprehensive after-sales service system to enhance brand reputation[97].

Financial Performance - Total revenue for Q1 2019 was CNY 105,820,606.40, representing an increase of 18.89% compared to CNY 89,009,549.04 in the same period last year[7]. - Net profit attributable to shareholders was CNY -20,827,377.48, a decrease of 3.28% from CNY -20,165,435.64 year-on-year[7]. - Basic and diluted earnings per share were both CNY -0.0484, a decrease of 3.20% from CNY -0.0469 in the same period last year[7]. - The company's operating profit was -27.78 million, a decrease of 15.92% year-on-year[19]. - Net profit for the current period was a loss of ¥26,208,038.73, compared to a loss of ¥20,906,837.22 in the previous period, worsening by about 25.4%[49]. - Operating profit for the current period was a loss of ¥27,784,518.76, compared to a loss of ¥23,968,296.76 in the previous period, reflecting a decline of approximately 15.1%[49]. - Total comprehensive loss for the current period was ¥26,208,038.73, compared to a loss of ¥20,906,837.22 in the previous period, indicating an increase in losses of about 25.4%[50]. Cash Flow - Net cash flow from operating activities was CNY -122,909,482.46, reflecting a decline of 25.54% compared to CNY -97,904,388.14 in the previous year[7]. - Total cash inflow from operating activities was 133,405,531.01 CNY, while cash outflow was 256,315,013.47 CNY, resulting in a net cash flow deficit[57]. - Cash flow from investing activities showed a net outflow of -5,036,043.18 CNY, compared to -1,393,395.94 CNY in the previous period, reflecting increased investment expenditures[58]. - Cash inflow from financing activities was 91,000,000.00 CNY, with a net cash flow of 45,204,889.53 CNY, a significant increase from 4,945,818.71 CNY in the previous period[58]. - The ending balance of cash and cash equivalents decreased to 243,040,610.00 CNY from 311,289,735.85 CNY, indicating a reduction in liquidity[58]. - The company received 90,150,000.00 CNY from borrowings, up from 80,000,000.00 CNY in the previous period, showing reliance on debt financing[62]. - Total cash inflow from operating activities was 105,759,629.46 CNY, down from 182,858,402.94 CNY, indicating a decline in revenue generation[61]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,915,622,997.37, a slight increase of 0.03% from CNY 1,914,957,108.71 at the end of the previous year[7]. - Current liabilities totaled CNY 808,432,841.84, up from CNY 781,284,873.36, reflecting an increase of approximately 3.9%[40]. - The company's total liabilities reached CNY 1,107,530,164.59, an increase from CNY 1,081,506,237.20, marking a growth of about 2.3%[40]. - Total liabilities reached CNY 1,081,506,237.20, with current liabilities at CNY 781,284,873.36[65]. - The company’s retained earnings were reported at CNY 250,158,960.13[65]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,281[10]. - The top shareholder, Zhang Xi, holds 16.21% of the shares, amounting to 69,681,649 shares, with 52,261,237 shares pledged[10]. - Micro Medical Group increased its shareholding to 41,200,000 shares, representing 9.58% of the total share capital as of March 31, 2019, up from 21,000,000 shares or 4.88% prior to the increase[29]. - The company’s major shareholder, Zhang Xi, retained 128,875,867 shares, accounting for 29.97% of the total share capital after the transfer of 36,775,000 shares[26]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[11]. Operational Highlights - The company plans to enhance its core competitiveness through continuous R&D of new technologies and products[22]. - The company is actively expanding its business in the healthcare sector, public services, and big data fields to increase market share[19]. - The company has implemented measures to mitigate technology risks, including patent applications and internal confidentiality systems[22]. - Research and development expenses rose to ¥29,615,998.59, up from ¥23,188,014.68, indicating a growth of approximately 27.7%[47]. Other Financial Metrics - Other receivables increased by 49.15% compared to the beginning of the year, mainly due to new factoring business interest[17]. - Inventory increased by 48.24% compared to the beginning of the year, primarily due to the increase in project equipment[17]. - Investment income increased by 61.79% year-on-year, mainly due to profits from certain affiliated companies[18]. - Other income increased to ¥4,733,035.81 from ¥1,856,697.74, marking a growth of about 154%[47]. - The company incurred financial expenses of ¥3,551,134.28, down from ¥4,500,865.83, a decrease of approximately 21%[47].

Financial Performance - The company's operating revenue for 2018 was ¥729,805,790.24, representing a 16.67% increase compared to ¥625,540,124.27 in 2017[17]. - The net profit attributable to shareholders for 2018 was ¥14,664,775.38, a decrease of 19.08% from ¥18,121,725.29 in the previous year[17]. - The net cash flow from operating activities reached ¥56,774,366.09, a significant increase of 6,163.56% compared to -¥936,320.35 in 2017[17]. - The total assets at the end of 2018 were ¥1,914,957,108.71, showing a slight increase of 0.25% from ¥1,910,237,184.55 at the end of 2017[17]. - The net assets attributable to shareholders increased by 1.84% to ¥740,647,483.83 at the end of 2018, compared to ¥727,272,623.62 at the end of 2017[17]. - The basic earnings per share for 2018 was ¥0.0340, down 19.05% from ¥0.0420 in 2017[17]. - The company reported a total of ¥8,245,989.04 in non-recurring gains and losses for 2018, compared to ¥60,964,213.70 in 2017[23]. - The company's total revenue for 2018 reached approximately 1.1 billion yuan, with a significant increase in the fourth quarter due to project completions[62]. - The net profit attributable to shareholders for the fourth quarter was approximately 31.8 million yuan, marking a recovery from previous losses in earlier quarters[62]. - The company reported a total revenue of 1,724,181,890 for the year, with a net profit of 272,409,605, indicating a profit margin of approximately 15.8%[96]. Dividend Distribution - The company plans to distribute a cash dividend of 0.05 CNY per 10 shares to all shareholders, based on a total of 430,000,000 shares[4]. - The cash dividend distribution accounted for 100% of the profit distribution total, aligning with the company's policy of distributing at least 80% of profits during mature stages[119]. - In 2018, the cash dividend amount was CNY 2,150,000, representing 14.66% of the net profit attributable to ordinary shareholders[122]. - In 2017, the cash dividend amount was CNY 2,150,000, which accounted for 11.86% of the net profit attributable to ordinary shareholders[122]. - In 2016, the cash dividend amount was CNY 2,150,000, making up 20.29% of the net profit attributable to ordinary shareholders[122]. - The company maintained a consistent cash dividend policy over the past three years, with each year distributing 2,150,000 yuan[120]. Operational Strategy - The company plans to continue focusing on technological innovation and market expansion in the upcoming year[24]. - The company aims to leverage the government's focus on health care informationization to enhance its market position and expand its services[30]. - The company is actively exploring the integration of new technologies like cloud computing and big data into its health service offerings[27]. - The company aims to leverage big data to enhance its service offerings in healthcare and social security sectors, focusing on disease outbreak warnings and employment decision analysis[38]. - The company is focusing on integrating its core business areas, including healthcare, social security, and big data, to enhance its competitive advantage[49]. - The company plans to continue exploring new service models in the public service sector, particularly in the integration of internet services with social security[54]. - The company aims to achieve a net profit margin of 10% by optimizing operational efficiencies and reducing costs[95]. Market Presence and Expansion - The company serves over 450 million individuals and more than 6 million enterprises across over 20 provinces in China[25]. - The company has established a strong presence in the health care sector, offering solutions such as smart hospital systems and health city solutions[31]. - The company has expanded its services to over 20 provinces and 100 cities, serving a population of more than 450 million[46]. - The company is focused on expanding its market presence in the healthcare and public service sectors, aiming to optimize service delivery and cost efficiency[99]. - The company plans to expand its market presence in southern China, targeting a 15% increase in market share by the end of the next fiscal year[95]. Research and Development - Research and development expenses amounted to ¥105,432,970.39, an increase of 11.01% compared to the previous year, primarily due to rising labor costs[77]. - The company invested ¥118,360,835.88 in R&D, which is 16.22% of its operating revenue, with capitalized R&D expenses of ¥12,927,865.49, accounting for 10.92% of total R&D expenses[78]. - In 2019, the company plans to increase R&D investment and enhance R&D efficiency to strengthen its competitive advantage and explore new business breakthroughs[103]. Compliance and Governance - The company has established a complete independent labor, personnel, and salary management system[126]. - The commitments regarding related party transactions have been strictly adhered to, with no violations reported[124]. - The company has taken measures to prevent conflicts of interest and ensure fair transactions[125]. - The company has committed to maintaining its independence and ensuring that key management personnel do not hold positions in other controlled enterprises[126]. - The company has established an independent financial department and accounting system, allowing for autonomous financial decision-making[128]. Technology and Innovation - The company has developed a comprehensive software and hardware application system, integrating online and offline services, driven by big data[25]. - The company has pioneered several industry-first innovations, including the first financial social security IC card and the first cloud computing platform for public service in the industry[42]. - The company is actively involved in the development of a "Internet + Healthcare" platform, with significant contracts signed in 2018[51]. - The company has launched several new products, including "Internet + Healthcare" services and big data integration platforms, to enhance its service offerings[100]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts, indicating potential risks and countermeasures in its operational outlook[4]. - The company is committed to enhancing its internal control system and risk prevention mechanisms to ensure stable operations[104]. - The company faces technology risks due to rapid changes in software and information technology, necessitating continuous R&D and product upgrades[106]. Shareholder Information - The company’s total share capital is 430,000,000 shares, with 376,521,705 shares being unrestricted[193]. - The largest shareholder, Zhang Xi, holds 16.21% of the shares, totaling 69,681,640 shares, with a pledge status on 69,606,549 shares[199]. - The company has a significant number of shares pledged, with Zhang Xi pledging 17,420,412 shares and Xiamen Linzhen Trading Co., Ltd. pledging 22,419,218 shares[198]. - The company’s major shareholders are primarily natural persons, with Zhang Xi being the controlling shareholder[200].

Financial Performance - Operating revenue for the reporting period was ¥180,644,547.52, representing a year-on-year increase of 56.64%[7] - Net profit attributable to shareholders was ¥3,418,720.05, a significant increase of 129.80% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,125,656.01, up 122.13% year-on-year[7] - Basic earnings per share for the reporting period was ¥0.0080, reflecting a 129.96% increase compared to the same period last year[7] - The company's operating revenue increased by 40.44% compared to the same period last year, driven by business growth[18] - Total operating revenue for Q3 2018 was CNY 180.64 million, an increase of 56.5% compared to CNY 115.33 million in the same period last year[34] - Net profit for Q3 2018 was CNY 8.34 million, compared to a net loss of CNY 10.67 million in Q3 2017, marking a significant turnaround[36] - The net loss attributable to the parent company for the year-to-date was CNY -17,159,190.55, compared to a loss of CNY -52,530,467.36 in the previous year[45] Cash Flow - The company reported a net cash flow from operating activities of -¥174,175,578.72, a decline of 2.22% year-to-date[7] - Cash inflow from operating activities totaled ¥518,420,202.70, while cash outflow was ¥692,595,781.42, resulting in a negative cash flow[49] - Cash and cash equivalents decreased by 34.32% from the beginning of the year, primarily due to net cash outflows from operating activities[20] - Cash inflow from financing activities totaled ¥450 million, with ¥165 million from borrowings and ¥176 million from other financing activities[55] - The net increase in cash and cash equivalents was -¥121 million, compared to -¥14.8 million in the previous period[55] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,915,610,029.85, an increase of 0.28% compared to the end of the previous year[7] - The company's total assets amounted to approximately CNY 1.92 billion as of September 30, 2018[28] - The total liabilities decreased to CNY 939.16 million from CNY 971.64 million, a reduction of about 3.3%[32] - The equity attributable to shareholders of the parent company decreased to CNY 707.96 million from CNY 727.27 million, a decline of 2.6%[32] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,373[10] - The top shareholder, Zhang Xi, holds 16.21% of the shares, amounting to 69,681,649 shares, with 52,261,237 shares pledged[11] Operating Costs and Expenses - Operating costs rose by 43.92% year-on-year, primarily due to increased costs associated with system integration and hardware business[18] - Total operating costs for Q3 2018 were CNY 178.35 million, up 36.7% from CNY 130.46 million in the previous year[34] - The company's total operating expenses increased, with research and development expenses at ¥3,253,997.69, down from ¥13,328,846.79 in the previous period[47] Research and Development - Development expenditures rose by 130.41% from the beginning of the year, reflecting increased investment in research and development[20] - The company reported a significant increase in research and development expenses, totaling CNY 24.60 million, compared to CNY 41.16 million in the previous year, indicating a focus on innovation despite the reduction[34] Non-Recurring Gains and Losses - The company recorded non-recurring gains of ¥5,713,677.15 during the reporting period[8] - The company reported an increase of 101.37% in other income year-on-year, primarily due to increased government subsidies[20] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[36]

Financial Performance - The company reported a revenue of 300 million RMB for the first half of 2018, representing a year-on-year increase of 15% compared to the same period in 2017[14]. - The net profit attributable to shareholders for the first half of 2018 was 50 million RMB, an increase of 10% year-on-year[14]. - Total revenue for the reporting period was ¥257,303,345.98, representing a 30.94% increase compared to ¥196,502,502.16 in the same period last year[19]. - Net profit attributable to shareholders was -¥20,577,910.60, an improvement of 49.88% from -¥41,057,967.09 year-on-year[19]. - The company achieved a revenue of 257.30 million yuan in the first half of 2018, representing a year-on-year increase of 30.94%[42]. - The company's operating profit was -23.26 million yuan, showing a year-on-year improvement of 53.79%[42]. - The net loss for the first half of 2018 was CNY 19,429,641.17, compared to a net loss of CNY 41,218,772.04 in the same period of 2017, indicating an improvement in performance[158]. Investment and R&D - The company plans to invest 20 million RMB in research and development for new technologies and products in the upcoming year[14]. - The company’s development expenditure increased by 68.94%, reflecting increased investment in research and development[36]. - The company's R&D investment increased by 33.43% to ¥47,835,745.13, reflecting a commitment to enhancing research activities[48]. - Continuous investment in technology and product development is crucial for the company's growth, with a focus on maintaining a leading position in core technologies[72]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting three new provinces by the end of 2019[14]. - The company is exploring potential mergers and acquisitions to enhance its market position and service offerings[14]. - The company is focusing on strategic upgrades driven by big data in health care, public services, and industrial finance[26]. - The company aims to enhance product technology and service quality while increasing market promotion efforts[30]. - The company is actively exploring new technologies such as big data, blockchain, and biometric identification to enhance its service offerings[42]. User and Service Growth - User data showed a growth of 25% in active users, reaching 1.5 million by the end of June 2018[14]. - The company serves over 450 million people and more than 6 million enterprises across more than 20 provinces[26]. - The company has expanded its services to over 450 million people across more than 100 cities in over 20 provinces[40]. - The company has established internet medical project teams to expand into the internet healthcare sector, including smart hospitals and remote medical services[29]. Financial Position and Assets - Total assets at the end of the reporting period were ¥1,955,587,673.14, up 2.37% from ¥1,910,237,184.55 at the end of the previous year[19]. - The company's total assets at the end of the period amounted to RMB 632,149,102.15, an increase from the beginning balance[182]. - The company's current assets totaled RMB 1,363,788,695.03, compared to RMB 1,311,172,759.03 at the start of the period, reflecting a growth of approximately 4%[148]. - The company's total liabilities were RMB 1,196,830,114.06, up from RMB 1,142,219,984.30, indicating a rise of about 4.8%[149]. Shareholder and Equity Information - No cash dividends or stock bonuses will be distributed to shareholders for this period[5]. - The company did not distribute cash dividends or issue new shares from capital reserves during the reporting period[79]. - The total number of shares outstanding is 430,000,000, with 12.44% being limited shares and 87.56% being unrestricted shares[126]. - The company has a total of 10 major shareholders, with no new strategic investors or general corporate entities becoming major shareholders during the reporting period[131]. Risks and Challenges - The company is facing risks related to market competition and regulatory changes, with strategies in place to mitigate these risks[4]. - The company is facing increased competition in the internet healthcare sector, prompting a strategic push to enhance its core competitive advantages[73]. - The company is facing human resource risks due to high employee turnover and competition for skilled talent, which could impact operations[74]. Corporate Governance and Compliance - The company has not experienced any penalties or corrective actions during the reporting period[87]. - The company has no major litigation or arbitration matters during the reporting period[84]. - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring compliance and accuracy[186]. Subsidiaries and New Ventures - The company established a new subsidiary, Haibao Life Insurance Co., Ltd., which has commenced operations during the reporting period, enhancing its financial service offerings[44]. - The company has established Fujian Yilianzhong Yidaxun Education Technology Co., Ltd. with a registered capital of RMB 50 million, where the company contributed RMB 32.5 million (65%) and the vice president contributed RMB 17.5 million (35%)[94]. - The company also set up Yilianzhong Liankang (Xiamen) Information Technology Co., Ltd. with a registered capital of RMB 5 million, with the company investing RMB 3.25 million (65%) and the vice president investing RMB 1.75 million (35%)[95].

Financial Performance - Total revenue for Q1 2018 was ¥89,009,549.04, representing a 59.23% increase compared to ¥55,901,365.53 in the same period last year[7] - Net profit attributable to shareholders was -¥20,165,435.64, an improvement of 17.87% from -¥24,553,950.44 year-on-year[7] - The company's revenue increased by 59.23% compared to the same period last year, primarily due to the expansion of business scale in software and IC card operations, as well as in the human resources industry[21] - The net profit attributable to shareholders was -20.17 million RMB, an increase of 17.87% year-on-year[23] - The net profit for the current period was a loss of ¥20,906,837.22, an improvement from a loss of ¥24,488,182.21 in the previous period[49] - The net profit for Q1 2018 was a loss of ¥13,313,871.79, slightly improved from a loss of ¥13,574,549.87 in Q1 2017, indicating a reduction in losses of about 1.9%[52] Cash Flow - The net cash flow from operating activities was -¥97,904,388.14, a slight decrease of 3.00% compared to -¥95,051,593.03 in the previous year[7] - The net cash flow from operating activities decreased by 2.85 million RMB compared to the same period last year, mainly due to a reduction in receivables collection and an increase in payments to suppliers[21] - The cash flow from operating activities showed a net outflow of ¥97,904,388.14, compared to a net outflow of ¥95,051,593.03 in the previous year, reflecting a deterioration of approximately 3%[55] - The company reported a significant increase in cash paid for operating activities, totaling 100,581,065.47 CNY, compared to 269,493,943.58 CNY in the previous year[59] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,862,998,128.93, down 2.47% from ¥1,910,237,184.55 at the end of the previous year[7] - The net assets attributable to shareholders decreased by 2.77% to ¥707,107,187.98 from ¥727,272,623.62 at the end of the previous year[7] - The company's total equity was CNY 755,855,363.03, down from CNY 768,017,200.25, reflecting a decrease of about 1.6%[42] - The total liabilities increased to ¥1,013,953,318.01 from ¥971,643,348.36, indicating a rise in financial obligations[45] Shareholder Information - As of the end of the reporting period, the total number of common stock shareholders was 24,814[14] - The largest shareholder, Zhang Xi, holds 16.21% of the shares, amounting to 69,681,649 shares, with 52,261,237 shares pledged[14] - The top 10 shareholders collectively hold significant stakes, with the second-largest shareholder holding 8.55%[14] - The company has a total of 53,478,295 restricted shares, with specific release conditions for executives[18] Operational Strategy - The company faces technology risks due to rapid updates in software and product lifecycles, necessitating continuous R&D efforts[9] - The company is actively upgrading to an internet operation model to maintain its leading position in the industry, which involves significant investment and time[11] - The company has established a comprehensive after-sales service system to enhance its brand image and address operational risks[9] - The company is focusing on enhancing its core technology competitiveness through increased investment in talent and R&D[11] - The company has implemented a new management structure to improve operational flexibility and control over strategic direction and risks[12] - The company plans to continue expanding its business and exploring new technologies in the upcoming quarters[21] - The company is actively expanding its business in healthcare, public services, and big data sectors to enhance its competitive advantage[22] Financial Activities - The net cash flow from investing activities decreased by 74.26% year-on-year, primarily due to reduced investments in associated companies[21] - The net cash flow from financing activities increased by 22.1% compared to the same period last year, mainly due to increased investments from minority shareholders[21] - The financing activities generated a net cash inflow of ¥4,945,818.71 in Q1 2018, compared to ¥4,050,725.00 in Q1 2017, reflecting an increase of approximately 22.1%[56] - The company incurred financial expenses of ¥4,095,120.56 in Q1 2018, significantly higher than ¥528,993.84 in Q1 2017, marking an increase of about 675%[51] Compliance and Governance - The company has no overdue commitments from shareholders or related parties during the reporting period[32] - There were no violations regarding external guarantees during the reporting period[34] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[35] - The company is in compliance with its profit distribution policy as per its articles of association[33]